MyFinsight
Home
Blog
About
Back
Cash Flow
Processa Pharmaceuticals, Inc. (PCSA)
Processa Pharmaceuticals, Inc. (PCSA)
source: myfinsight.com
Net proceeds from
issuance of common stock
$315,167
Cash received from
sale of digital...
$186,000
Net cash provided by
financing activities
$315,167
(-97.07%↓ Y/Y)
Net cash used in
investing activities
$186,000
Net (decrease)
increase in cash and cash...
-$1,494,718
(-126.02%↓ Y/Y)
Canceled cashflow
$501,167
Accounts payable
$819,068
(961.03%↑ Y/Y)
Unrealized loss on digital
assets
$768,348
Realized loss on sale of
digital assets
$159,005
Stock-based compensation
$92,105
(-78.63%↓ Y/Y)
Depreciation
$301
(-50.00%↓ Y/Y)
Net cash used in
operating activities
-$1,995,885
(60.08%↑ Y/Y)
Canceled cashflow
$1,838,827
Net loss
-$3,265,494
(51.75%↑ Y/Y)
Accrued expenses
-$412,258
(-160.23%↓ Y/Y)
Prepaid expenses and
other
$156,960
(121.04%↑ Y/Y)
Back